GSK rises Tuesday, outperforms market
Shares of GSK PLC GSK inched up 0.33% to £13.59 Tuesday, on what proved to be an all-around positive trading session for the ...
Anywhere under £45.27, GSK’s share price looks cheap to me
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
GSK (NYSE:GSK) Stock Rating Lowered by StockNews.com
GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...
FierceBiotech9d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
STAT9d
Pharmalittle: We’re reading about J&J and GSK deals, a departing FDA official, and more
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
GSK: European Commission Expands Jemperli Plus Chemotherapy Approval - Quick Facts
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
FierceBiotech7d
JPM25: GSK’s CSO shares science strategy behind deal-heavy year
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...
BioSpace9d
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
GSK rises Thursday, outperforms market
Shares of GSK PLC GSK advanced 1.58% to £13.49 Thursday, on what proved to be an all-around favorable trading session for the ...